middle.news
Immutep Doses First Patient in Landmark Phase III Lung Cancer Trial
6:19am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Immutep Doses First Patient in Landmark Phase III Lung Cancer Trial
6:19am on Monday 2nd of June, 2025 AEST
Key Points
First patient dosed in TACTI-004 Phase III trial for advanced NSCLC
Patient enrolment completed in EFTISARC-NEO and INSIGHT-003 trials
TACTI-004 trial design presented at European Lung Cancer Congress 2025
Strong cash position of A$146.25 million with runway to end of CY2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE